- Ixekizumab in the treatment of psoriatic arthritis2018 | First Faculty of Medicine
- Ixekizumab - a new first-line drug of biological therapy for psoriasis2018 | Second Faculty of Medicine
- Long-term outcomes of ixekizumab treatment in patients with axial spondyloarthritis2023 | First Faculty of Medicine
- Kazuistika pacienta s psoriatickou artritidou léčeného ixekizumabem -klouby, kůže i nehty pod kontrolou2023 | First Faculty of Medicine
- Adalimumab biosimilar-induced severe paradoxical palmoplantar pustulosis in a patient with psoriasis and psoriatic arthritis successfully treated with ixekizumab2022 | Third Faculty of Medicine
- Challenging therapy of severe psoriasis and psoriatic artrtitis2018 | Faculty of Medicine in Pilsen
- Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry2022 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine, Central Library of Charles University
- 6 Ixekizumab v léčbě genitální psoriázy2021 | Third Faculty of Medicine
- Inhibition of IL-17 - a new approach in the biological treatment of spondyloarthritides2017 | First Faculty of Medicine
- Crohn’s disease in a young psoriatic patient previously exposed to ixekizumab2021 | Second Faculty of Medicine
- Ixecizumab (TALTZ (R)) - a new drug for the treatment of psoriasis2017 | Second Faculty of Medicine
- Current Approach to Modern Treatment of Psoriasis - Updated Guidelines of ČDS JEP for Targeted Treatment of Severe Chronic Psoriasis2019 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine
- Efficacy of switches within the class of IL-17 inhibitors: An analysis of data from the Czech nationwide registry of psoriatic patients receiving biological/targeted therapy (BIOREP)2022 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine, Central Library of Charles University
- Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study2021 | Third Faculty of Medicine
- British Association of Dermatologists guidelines for biologic therapy for psoriasis 20172017 | Faculty of Medicine in Pilsen
- IL-17 inhibitors in psoriasis treatment2022 | Third Faculty of Medicine
- What we can do for a patient with psoriatic arthritis when TNF inhibitors fail2019 | First Faculty of Medicine
- Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study2022 | Third Faculty of Medicine
- Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study2021 | Third Faculty of Medicine
